INTRODUCTION {#S5}
============

TB, caused by Mtb, remains a major public health threat globally, with a high burden in Sub-Saharan Africa. According to the World Health Organization, in 2011, Uganda\'s TB incidence rate was 193 per 100,000 people, compared to 3.9 per 100,000 in the United States (<http://www.who.int/tb/country/data/profiles/en/>).

Exposure to Mtb initiates the first steps in the pathogenesis of Mtb infection and subsequent active TB. Tuberculin skin tests (TST) and interferon-γ release assays (IGRA) measure T-cell responses to Mtb and are utilized to identify Mtb-infected individuals. Infected individuals can remain healthy and without signs of active infection or disease (termed latent tuberculosis infection or LTBI), or progress to active TB. Only about 10% of healthy adults with Mtb infection develop active TB. Notably, using the TST as a marker for Mtb infection, we have found that \~10% of individuals who are household contacts of patients with pulmonary TB, remain uninfected for at least 2 years ([@R1];[@R2]). Our TB household contact study is unique in that it has rigorously characterized resistance to Mtb infection in the face of persistent exposure with a 2 year follow-up period in both the household and TB-endemic community.

Human genetic susceptibility is involved in the pathogenesis of TB, with most research focusing on immune response genes ([@R3];[@R4]). Previous research has shown that chromosomal regions linked to TB differed from those linked to resistance to Mtb infection ([@R2]). In this study, we examined this hypothesis further, by contrasting results of two analyses: 1) presence versus absence of active TB, and 2) resistance versus susceptibility to Mtb infection. Mtb uninfected individuals are characterized by a persistently negative TST (PTST-) over an extended period of exposure, and are referred to as resistors (RSTRs). Our previous work has shown that these persistently TST negative individuals have equivalent epidemiologic risk profiles to those who have positive TSTs, including exposure to the index TB case and clinical characteristics ([@R5]). In that study, we found the primary predictor of RSTR was young age, and we hypothesized that host factors, such as genetics and innate immunity, likely also influenced the RSTR phenotype.

Numerous studies have informed our understanding of the role of host genetics in susceptibility to Mtb infection and disease. There are several classes of genes that are important for host responses to TB ([@R6];[@R7]). These include the Toll-like and Nod-like receptor families of genes (TLR1, TLR2, TLR4, TLR6, TLR9, TIRAP, TOLLIP,TICAM1/2, MyD88, NOD1, NOD2), cytokines and their receptors expressed by macrophages (*TNF, TNFR1/2, IL1α/*β*, IL4, IL6, IL10, IL18*, *IL12A/B, IL12RB1/2*, *IFNG, IFNGR1/R2*), genes expressed by T-cells (*IFNG, IL4, IL12, STAT1, IL12RB1/2, IL10*), and key TB candidate genes (*SLC11A1, SLC6A3*). Many genes in these pathways have been studied extensively in animal, macrophage, and human studies and have shown varying degrees of association with TB, while others have not received much attention ([@R3];[@R4];[@R6];[@R7]).

Typically, studies exploring TB and genetic risk factors for disease have focused on a few polymorphisms within a few candidate genes. As a field, it is critical to examine genetic influences for developing TB broadly, validate other genetic findings, and avoid single candidate gene studies unless accompanied by validation and/or biology ([@R8]). In our current study, we have taken a comprehensive approach to the examination of genetic susceptibility to TB by investigating haplotype-tagging single nucleotide polymorphisms (SNPs) in multiple candidate genes involved in innate and/or adaptive immune pathways that affect host responses to mycobacterial invasion. The objective of our current study was to examine the association between these candidate genes and pulmonary TB and RSTR phenotypes within the context of a TB household contact cohort. Finally, our inclusion of household contacts of all ages and regardless of HIV status allowed us to explore the hypothesis that pediatric TB is different from adult TB in its genetic risk profile ([@R9]-[@R11]), and to explore the impact of HIV-infection on the TB genetic risk profile. The field of pediatric TB has been neglected and this study provides a unique opportunity to examine effects specific for children.

RESULTS {#S6}
=======

Genetic association with TB {#S7}
---------------------------

We first examined whether 546 haplotype tagging SNPs in 29 immune pathway genes were associated with TB in 835 subjects from 481 families within 298 households ([Table 1](#T1){ref-type="table"}). 240 individuals (28.7%) had TB (43% of the pediatric TB cases were culture positive, data not shown). The mean age was 18.43 (median=17) and 15% were HIV+. The percentage of HIV+ individuals within each group was similar, with 15% HIV+ in the TB analysis and 13% HIV+ in the RSTR analysis (data not shown).

Genetic association analysis with pulmonary TB as the outcome of interest showed two SNPs met the studywide significance threshold, with 19 additional SNPs showing a nominally significant association (p \< 0.05) ([Table 2](#T2){ref-type="table"}). The top SNPs in the TB analysis included 1 SNP within *TICAM2* (aka *TRAM*) in the 5' region, rs746566 (OR= 1.42, p=3.6×10^−6^) and 1 SNPs in *IL1B*, rs1143643 (OR=1.99, p=4.3×10^−5^). Multiple SNPs were associated with TB at the nominal p \< 0.05 level in *IL4* (best p=6.9×10^−3^), *NOD1* (p= 9.4×10^−3^), and *TOLLIP* (p =6.8×10^−3^). Allele frequencies in cases and unaffected individuals for SNPs significant at nominal p \< 0.05 are provided in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}, and results for all SNPs in *TICAM2* and *NOD1* are provided in [Supplemental Table 2](#SD1){ref-type="supplementary-material"}. To assess the impact of phenotype definition (both TST+ and RSTRs within the "control" group), we conducted a sensitivity analysis, restricting the controls to only TST+ individuals. The trend in results remained the same, albeit with reduced significance, because of the reduced sample size (data not shown).

While the association with *IL1B* has been reported in the literature before ([@R12];[@R13]) , the associations with *TICAM2* and *NOD1* have not, so we sought to replicate these findings in an independent cohort. We obtained the Wellcome Trust (WTCCC) TB genome-wide association study data ([@R14]) and examined SNPs in *TICAM2* and *NOD1* ([Supplemental Table 3](#SD1){ref-type="supplementary-material"}); this population (Gambia) is the same that previously showed an association with *IL1B* ([@R12]). Among the 42 SNPs in/near *TICAM2* that passed QC, five showed significant association with TB with uncorrected p-value \< 0.05. The most significant SNP was rs1005551 with p=0.024 with adjustment for sex and tribe, which meets the threshold for independent replication ([@R15]). Among the 23 SNPs in/near *NOD1* that passed QC, four were associated with TB with p-value \< 0.05 ([Suppl. Table 4](#SD1){ref-type="supplementary-material"}), with the most significant SNP being rs42603 with p=0.00096 adjusting for sex and tribe, also meeting the threshold for independent replication.

Examination of age-specific effects with TB {#S8}
-------------------------------------------

To assess whether genetic determinants of infection and disease were age-dependent, we used a genotype-age interaction analysis. Our primary focus here was on the interaction term of the model, since main effects cannot be interpreted independently in models with interaction terms. Six genes showed an association with TB in children, but not in adults ([Table 3](#T3){ref-type="table"}). The interaction term for rs2043055 (*IL18* intron) attained suggestive significance (p=2.9×10^−3^), only one level of magnitude lower than the threshold for studywide significance (p=2×10^−4^), and 2 additional SNPs approached this same level of significance. Association with *IL18* was not observed in the sample as a whole ([Table 2](#T2){ref-type="table"}). In addition, 3 SNPs within *TLR6* were suggestively associated with pediatric TB at this same level, with the most significant result at *TLR6* 3' SNP rs5743832 (p=2.7×10^−3^). One SNP within *IL1A*, 1 within *IL1B*, 5 within *STAT1*, 3 within *TLR6*, 2 within *IL12B*, 1 within *TLR4*, and 4 SNPs within *IL18* were nominally (uncorrected p\< 0.05) associated with pediatric TB.

Genetic association with RSTR {#S9}
-----------------------------

We next examined whether the same set of SNPs was associated with RSTR in 718 individuals, including 75 individuals (10.5%) who were RSTR. None of the SNPs met the experiment-wide significance level in the analysis with RSTR as the phenotype ([Table 4](#T4){ref-type="table"}). However, 17 SNPs showed a nominal association, at the p \< 0.05 level. The top SNPs in this analysis included 2 SNPs in *NOD1*, 2 SNPs in *NOD2*, and 3 SNPs in *SLC6A3*. *STAT1* was associated with RSTR in the sample as a whole, though it was associated with TB in the pediatric sample ([Table 3](#T3){ref-type="table"}). To make sure that HIV seropositivity did not influence the results (eg. anergy resulting in negative TSTs), we conducted a sensitivity analysis, excluding the HIV+ individuals from this analysis, and found no difference in significance (data not shown). In the age x genotype analysis for RSTR ([Table 5](#T5){ref-type="table"}), several SNPs in both *IL12RB1* and *IL12RB2* had significant interaction effects (p \< 0.01). These SNPs were associated with increased odds of RSTR in adults versus decreased odds of RSTR in children, or vice versa. Generally, these effects were only significant in adults or children.

DISCUSSION {#S10}
==========

Our study examined the association between 29 candidate genes involved in innate immune responses, and two distinct phenotypes that result as a consequence of Mtb exposure: resistance to infection and pulmonary TB. We identified novel associations between pulmonary TB and *TICAM2*; to our knowledge, we are the first to observe associations between this gene and TB, and we replicated this finding in an independent dataset. Moreover, we observed several SNPs with p\<10^−2^ in *NOD1* that were associated with TB. Although our results for *NOD1* did not achieve significance after multiple testing correction, this is the first report of an association between TB and *NOD1*, which we also replicated in an independent cohort. In addition, we observed novel suggestively significant interactions between SNPs in *IL18* and *TLR6* and age; these SNPs were associated with TB in children ≤10 years old. Finally, we observed two SNPs in *TOLLIP* associated with TB (p\<0.05), consistent with earlier findings ([@R16]).

Three SNPs within the *TICAM2* gene were associated with TB with one SNP significant at the experiment-wide threshold. In addition, one *TICAM2* SNP was nominally associated with RSTR. *TICAM2*, also known as *TRAM*, is a toll-like receptor adaptor that supports TLR4-mediated immune responses ([@R17]). In a recent study, TICAM2 levels predicted with 80% accuracy whether subjects would be high or low responders to the MVA85A TB vaccine candidate ([@R18]). Ours is the first study to find an association with *TICAM2* genetic variants and TB. In addition, we replicated association with *TICAM2* SNPs (p\<0.05) in the WTCCC data ([@R14]). Though our most significant SNP did not replicate, this may be due to differences in population genetic differences such as LD patterns and/or differences in ascertainment of cases and controls, as well as the design of the genotyping arrays (see [Supplemental Material](#SD1){ref-type="supplementary-material"} for detail) ([@R8]); a nearby *TICAM2* SNP, rs17473484, which is \~7 kb away, showed p=0.034, and another rs10055514, \~51.5 kb away, showed p=0.039.

We observed a statistically significant association between TB and *IL1B*, more significant than in previous reports and in intronic rather than exonic variants ([@R12];[@R13]). Intronic SNPs in *IL4* were also associated with TB. This is the first report of an association of *IL4* polymorphisms with TB in an African population and replicates studies of *IL4* in TB in non-Africans ([@R19];[@R20]). Our greater SNP density and use of haplotype-tagging SNPs allowed us to detect these genetic association effects ([@R8];[@R21]). This greater coverage of genetic variation may explain why we achieved greater significance than in previous reports ([@R12];[@R13]).

We investigated children age ≤10 years based on reports of age-specific genetic effects for TB ([@R9];[@R10]), differences in immune responses of children compared to adults ([@R22]), and unique epidemiological risk profiles for Mtb infection in children ([@R5]). We found an association between TB and *IL18* and *TLR6* in children, and suggestive associations between *TLR4* and *IL12B* and pediatric TB. Since most TB genetics studies focus on adults, this may explain why associations between TB and *IL18* have not been reported before. IL18, similar to IL1β, is a pro-inflammatory cytokine that requires activation of the host cell inflammasome for secretion in its mature, bioactive form ([@R23]). Mature IL18 has a role in development of Th-1 type immune responses, and with IL12 regulates IFN-γ production by T cells and NK cells ([@R24]). Although IFN-γ and IL1β are considered essential for control of Mtb, the role of IL18 in immune responses to Mtb remains unclear. Some murine models have demonstrated a protective role for this cytokine following *in vivo* Mtb infection ([@R25]), and human *in vitro* studies suggest that IL18 synergizes with IL12 to provide optimal control of Mtb in human macrophages ([@R26]). The only previously reported association between *IL18* and TB came from a meta-analysis of Chinese studies ([@R27]).

The association between genetic variation in *TLR6* and TB has been investigated in a few prior reports. A meta-analysis of 4 study populations (3 ethnically diverse populations in the United States and an Indian population) showed modest association between a *TLR6* polymorphism and TB, though these populations were presumably all adults ([@R28]). In young infants, *TLR6* polymorphisms have also been associated with altered BCG-specific cytokine responses ([@R29]), particularly post-BCG vaccination ([@R30]). The causal SNP implicated by Randhawa et al., rs5733810, is in moderate LD with rs5743812 in Kenyan HapMap data. We observed association between rs5743812 and pediatric TB, but did not genotype the those two SNPs ([@R30]), so cannot examine LD in the Ugandan population. Furthermore, we did not observe association with *TLR1*, which is in strong LD with *TLR6* in certain populations ([@R31]); given the lower LD seen in the Ugandan population ([@R32]) and non-significant association with *TLR1*, these effects are likely due to *TLR6* alone. Previously, we have detected signatures of natural selection in *TLR6* in Ugandans ([@R32]), suggesting this gene may be important in infectious disease susceptibility. Regarding the contribution of TLR6 to innate control of Mtb infection, there has been one report demonstrating that recognition of Mtb by TLR2/TLR6 heterodimers contributes to activation of the host cell inflammasome, caspase-1 activation, and subsequent production of mature IL1β ([@R33]). Since children ≤10 years are more likely to experience their first exposure to Mtb than adults living in TB endemic settings, genetic susceptibility to TB may differ whether the host has pre-existing immune sensitization to Mtb. Given the borderline p-values of some of our findings, our conclusion that they reflect unique age-based genetic susceptibility to TB may be premature. Our findings emphasize the importance of including children in genetic susceptibility studies, especially for diseases such as TB where disease risk and phenotype change as children grow older and their immune systems mature.

Though not significant at the experiment-wide threshold, SNPs from both *NOD1* and *NOD2* were associated with TB and the RSTR phenotype, respectively. One study in a Chinese population identified a single SNP in *NOD2* gene associated with TB susceptibility ([@R34]), although we observed an association between this gene and RSTR. NOD2, a cytosolic pattern recognition receptor, has been implicated in recognition of Mtb products that are secreted from the macrophage phagosome into the cytosol. Thus, NOD2 may play a role in activation of the host cell inflammasome with subsequent production of mature IL1β and IL18 ([@R33];[@R35];[@R36]). Ours is the first study to report associations between *NOD1* and TB, and we replicated this finding in the WTCCC study data. Even though the *NOD1* SNPs did not achieve experiment-wide statistical significance, it is noteworthy because this is the first report of a possible role for NOD1, and no other studies have examined genetic influences on RSTR.

While many studies designed to uncover genetic associations with TB focus on TB, few have explored the genetic association or genetic linkage with the TST- phenotype ([@R2];[@R37]). Since most studies do not include tuberculin skin testing in the characterization of non-diseased individuals ([@R8]), there is usually no assessment of the unaffected subject\'s exposure and/or infection with Mtb. Our use of data from a longitudinal household contact study not only provides opportunity to collect follow-up data, but also confirms Mtb household exposure of all study participants ([@R38]). The RSTR phenotype is of special interest since these individuals do not appear to become infected by Mtb over a two-year period, despite heavy exposure to an individual with active pulmonary TB and residence in a high TB endemic area ([@R5]). Though we did not find any SNPs to be significantly associated with the RSTR phenotype at the p \<2×10^−4^ (studywide α =0.05) level, we did find a nominally significant association with three *SLC6A3* SNPs. This finding replicates the Cobat et al. cross-sectional study, conducted in South Africa, that associated *SLC6A3* with TST reactivity ([@R37]). Because we observed nominal associations between various genes and TB and not with RSTR, this further suggests these distinct clinical outcomes are regulated by different genetic mechanisms. It is possible that we did not detect significant genetic associations with the RSTR phenotype because the vast majority of RSTRs were young children, and the age-specific models may have been underpowered to detect an effect. Larger cohorts will be needed to more closely examine this trait. Lastly, the impact of HIV on the characterization of RSTR is not well known. TST positivity is defined using a lower threshold for HIV positive individuals, and in our previous work, we saw no difference in the distribution of HIV in RSTRs versus non-RSTRs ([@R5]). Because most of these study subjects were enrolled before CD4 counts were done in HIV positive individuals (pre 2004), we are unable to evaluate the impact of low CD4 and potential anergy in the RSTRs. Only 4 of the RSTRs were HIV+, so possible anergy likely had little influence on our findings.

Interestingly, we only observed one SNP within the 3' region of the *SLC11A1* gene (aka *NRAMP1*) that was associated with TB, and it did not achieve experiment-wide statistical significance (p=0.026). *SLC11A1* has been associated with TB in meta-analyses ([@R39]-[@R41]), so the lack of statistically significant associations might be surprising. Non-replication could be due to study design, including differences in diagnostic criteria for TB cases and controls and issues of targeted polymorphisms versus comprehensive LD coverage ([@R8];[@R15]). Another possible explanation for our weak association between TB and *SLC11A1* could be due to interactions between *SLC11A1* and other genes, where *TLR2* acted as a modifier of *SLC11A1*-associated TB risk ([@R42]).

Our findings are limited by our sample size and the fact that we had no Ugandan replication sample. Despite these limitations, we identified significant and novel associations between SNPs in immune response genes and TB, such as *TICAM2, NOD1*, and *IL1B*, as well as pediatric TB-specific effects for *IL18* and *TLR6*. Our findings warrant further study with a larger sample size. Our candidate gene, hypothesis-based approach, as opposed to a genome-wide analysis, may have prevented us from observing additional genes significantly associated with the RSTR phenotype, so further work is needed. Our age-based analysis suggests that genetic susceptibility for TB in adults and pre-adolescent children may differ and warrant further investigation in a larger cohort of Mtb-exposed children.

MATERIALS AND METHODS {#S11}
=====================

Study Participants {#S12}
------------------

Data used in this analysis was gathered from two phases of a household contact study conducted in Kampala, Uganda. Subjects from the Household Contact Study were enrolled from 1995-1999 ([@R43]) , while subjects from the Kawempe Community Health Study were enrolled from 2002-2008 ([@R38]). The study protocol was reviewed and approved by the National HIV/AIDS Research Committee, The Uganda National Council of Science and Technology, and the institutional review board at University Hospitals Case Medical Center, Cleveland, OH. Individuals who presented at the study clinic with active culture positive pulmonary TB were enrolled as index cases. All household members who provided informed consent were also enrolled and evaluated at study entry with TST, HIV testing, chest X-ray, and a history and physical exam for signs and symptoms of TB. Healthy household contacts underwent a follow-up evaluation every three months for the first six months, then every six months thereafter. Diagnosis of TB for this analysis was based on isolation of Mtb from clinical samples (sputum or gastric aspirates) of all adult patients and the many pediatric cases (44% of those in this analysis) ([@R44]) at any time during the study period. There were no individuals with disseminated TB (TB meningitis or miliary TB) included in this analysis. RSTR individuals were defined as having TSTs that remained negative throughout the two-year follow-up period. A positive TST was defined by induration at the injection site greater than 5mm for children ≤5 years old or HIV-infected individuals, and greater than 10mm for all others; the 10mm cutoff is used in settings where BCG vaccine coverage is high ([@R5];[@R45]).

Genotyping {#S13}
----------

In our analysis, we focused on 29 genes involved in the TNF, interleukin, TLR/NLR, and IFNG/IL12 pathways, genotyping 546 haplotype-tagging SNPs within these genes. Tag SNPs were selected to capture common genetic variation (minor allele frequency ≥ 5%) with strong coverage (linkage disequilibrium r^2^ ≥ 0.8) in any of the 3 African HapMap populations, based on our previous work ([@R32]), and were identified using Genome Variation Server (GVS) (<http://gvs.gs.washington.edu/GVS137/index.jsp>). Genotyping was conducted using the Illumina iSelect platform. Once SNPs were selected using GVS, their availability on the iSelect platform was verified; if a specific SNP was not available on iSelect, a nearby SNP was selected to replace it. Genotype calling and quality control was performed using Genome Studio, filtering the SNPs by call frequency, replicate errors, and clustering quality (AB R Mean, AB T Mean); 14 SNPs were removed in this process. Self-reported family relationships were confirmed using genetic data and corrected where needed.

Statistical Analysis {#S14}
--------------------

Sample allele frequencies were calculated adjusting for family structure by means of the maximum-likelihood approach implemented in FREQ, part of the S.A.G.E. package ([@R46]). Genetic association analyses were conducted by logistic regression using generalized estimation equations to account for genetic relatedness within households, as implemented in the R package gee. Observations were clustered by subfamily, defined as groups of first-degree relatives living within a household. Genetic association analyses were conducted separately to examine two distinct phenotypes: *active TB (versus absence of active TB)* and *RSTR (versus* *susceptibility to Mtb infection);* TST+ individuals without active disease were included in the control group for both analyses, and RSTRs did not have active TB by definition. Each subject had only one clinical classification (RSTR, TST+, or TB). Genotypes were coded as both additive and dominant genetic models, using the minor allele as the effect ("risk") allele. Recessive models were not tested because the rare allele homozygote was usually too infrequent for the models to be reliable. Sex and HIV status were included as covariates in all analyses. An exchangeable correlation matrix was used in the GEE model, except where the minor allele was too rare for the exchangeable model to converge to a maximum, in which cases an independence model was fitted. A single-SNP p-value of 2×10^−4^, corresponding to a study-wide significance threshold of α=0.05, was determined by estimating the number of independent tests based on LD among the SNPs passing QC ([@R47]) using the program SNPSpDlite (<http://gump.qimr.edu.au/general/daleN/SNPSpDlite/>).

We also conducted an analysis including an age x genotype interaction term to explore age-specific genetic effects, where age was a binary variable of age ≤ 10y. This age cutoff was based on similarity of epidemiological risk factor distribution within children ≤ 10 years of age compared to older children and adults ([@R5]). When the interaction term was significant, we conducted stratified analyses (separate models for age ≤ 10 and age \>10) to evaluate whether the significant genetic effect was in the children, adults, or both. Similarly, we conducted an HIV x genotype analysis, based on our earlier observation that HIV seropositivity may have a synergistic genetic effect on TB risk ([@R48]); these analyses were restricted to the TB phenotype, because there were too few HIV-infected individuals that were RSTR. Results did not attain statistical significance in the HIV-genotype interaction models ([Supplemental Table 5](#SD1){ref-type="supplementary-material"}).
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###### 

Sample characteristics^[a](#TFN1){ref-type="table-fn"}^

  ------------------------------------------- ------------------
  Total individuals                           835
  Families                                    481
  Female                                      485 (58.1%)
  Age, years                                  18.4 ± 13.6
  Age ≤ 10 years                              303 (36.3%)
  TB+                                         240 (28.7%)
      TB cases among Age ≤ 10                 35 / 303 (11.6%)
      RSTR^[b](#TFN2){ref-type="table-fn"}^   75 / 718 (10.4%)
  RSTRs among Age ≤ 10                        55 / 303 (18.2%)
  HIV+                                        122 (14.6%)
  ------------------------------------------- ------------------

Figures given as *N, N* (%) or mean ± SD.

The analysis of RSTR was restricted to a subset of individuals with complete tuberculin skin test follow-up data (*N* = 718 from 435 families).

###### 

Results of genetic association analysis of TB phenotype (SNPs with nominal p-values \<0.05)

  SNP          Gene        Location          OR (95% CI)         p                                               Best Model
  ------------ ----------- ----------------- ------------------- ----------------------------------------------- ------------
  rs2569254    *IL12B*     intron            1.75 (1.05, 2.90)   3.1E-02                                         Dom
  rs5744229    *IL18*      intron            1.63 (1.05, 2.51)   2.8E-02                                         Dom
  rs1143643    *IL1B*      intron            1.99 (1.43, 2.76)   **4.2E-05^[\*](#TFN3){ref-type="table-fn"}^**   Dom
  rs1143633    *IL1B*      intron            1.59 (1.13, 2.24)   7.7E-03                                         Dom
  rs2243270    *IL4*       intron            0.67 (0.51, 0.90)   6.9E-03                                         Dom
  rs2243274    *IL4*       intron            0.72 (0.53, 0.96)   2.8E-02                                         Dom
  rs2243290    *IL4*       intron            0.64 (0.45, 0.91)   1.3E-02                                         Dom
  rs17159043   *NOD1*      intron            1.56 (1.11, 2.17)   9.4E-03                                         Dom
  rs2970499    *NOD1*      intron            1.91 (1.17, 3.13)   9.8E-03                                         Dom
  rs13062      *SLC11A1*   flanking 3' UTR   1.48 (1.05, 2.09)   2.6E-02                                         Dom
  rs2550936    *SLC6A3*    intron            1.35 (1.04, 1.76)   2.4E-02                                         Add
  rs256946     *TICAM2*    flanking 5' UTR   0.67 (0.46, 0.99)   4.6E-02                                         Dom
  rs419939     *TICAM2*    flanking 5' UTR   0.79 (0.63, 0.99)   4.4E-02                                         Add
  rs746566     *TICAM2*    flanking 5' UTR   1.42 (1.22, 1.65)   **3.6E-06^[\*](#TFN3){ref-type="table-fn"}^**   Add
  rs4624663    *TLR1*      3' UTR            1.52 (1.02, 2.27)   4.2E-02                                         Dom
  rs11938228   *TLR2*      flanking 5' UTR   0.66 (0.44, 0.99)   4.4E-02                                         Dom
  rs5743818    *TLR6*      Coding A644A      0.52 (0.28, 0.96)   3.8E-02                                         Add
  rs4963062    *TOLLIP*    intron            1.44 (1.05, 1.98)   2.4E-02                                         Dom
  rs5743867    *TOLLIP*    intron            1.52 (1.12, 2.05)   6.8E-03                                         Dom

Experiment-wide significant (*p* \< 2 × 10^−4^)

###### 

Genotype x age interaction analysis of TB.

                                             Children^[\*](#TFN4){ref-type="table-fn"}^   Adults^[\*](#TFN4){ref-type="table-fn"}^   Interaction                                      
  ------------ ----------- ----------------- -------------------------------------------- ------------------------------------------ ------------------- -------- ------------------- --------
  rs2834210    *IFNGR2*    intron            1.44 (0.94, 2.21)                            0.091                                      0.81 (0.64, 1.04)   0.10     0.56 (0.35, 0.92)   0.023
  rs2834214    *IFNGR2*    intron            1.38 (0.84, 2.26)                            0.20                                       0.77 (0.60, 0.99)   0.045    0.56 (0.32, 0.98)   0.041
  rs2834215    *IFNGR2*    intron            1.34 (0.82, 2.20)                            0.24                                       0.74 (0.58, 0.96)   0.021    0.55 (0.32, 0.97)   0.037
  rs9808685    *IFNGR2*    intron            0.66 (0.43, 1.01)                            0.057                                      1.20 (0.95, 1.52)   0.13     1.83 (1.12, 2.98)   0.016
  rs3212220    *IL12B*     intron            0.49 (0.28, 0.87)                            0.014                                      0.99 (0.77, 1.28)   0.96     2.02 (1.08, 3.78)   0.028
  rs6894567    *IL12B*     intron            0.50 (0.30, 0.85)                            0.0096                                     0.93 (0.72, 1.19)   0.56     1.84 (1.03, 3.29)   0.039
  rs17887176   *IL12RB1*   coding P47S       0.36 (0.11, 1.20)                            0.096                                      1.40 (0.87, 2.25)   0.16     3.9 (1.14, 13.38)   0.030
  rs375947     *IL12RB1*   coding M365T      0.80 (0.48, 1.33)                            0.39                                       1.51 (1.15, 1.99)   0.0028   1.90 (1.06, 3.39)   0.031
  rs3761041    *IL12RB1*   intron            0.72 (0.38, 1.37)                            0.32                                       1.54 (1.11, 2.15)   0.010    2.13 (1.05, 4.32)   0.036
  rs12091150   *IL12RB2*   intron            0.59 (0.35, 1.01)                            0.056                                      1.14 (0.88, 1.47)   0.32     1.92 (1.06, 3.46)   0.031
  rs2307147    *IL12RB2*   coding D26D       0.59 (0.35, 1.00)                            0.051                                      1.13 (0.88, 1.46)   0.34     1.92 (1.07, 3.47)   0.030
  rs2043055    *IL18*      intron            0.55 (0.34, 0.88)                            0.013                                      1.22 (0.97, 1.52)   0.089    2.21 (1.31, 3.73)   0.0029
  rs360714     *IL18*      intron            0.49 (0.27, 0.88)                            0.018                                      1.11 (0.83, 1.48)   0.48     2.27 (1.18, 4.34)   0.014
  rs360722     *IL18*      intron            0.67 (0.41, 1.08)                            0.10                                       1.16 (0.91, 1.48)   0.22     1.75 (1.03, 2.96)   0.038
  rs3882891    *IL18*      intron            1.95 (1.19, 3.20)                            0.0084                                     0.87 (0.70, 1.10)   0.24     0.45 (0.26, 0.77)   0.0037
  rs5744280    *IL18*      intron            1.84 (1.12, 3.04)                            0.017                                      0.85 (0.66, 1.08)   0.19     0.46 (0.26, 0.80)   0.0058
  rs3783550    *IL1A*      intron            0.40 (0.19, 0.82)                            0.012                                      1.01 (0.74, 1.39)   0.93     2.55 (1.15, 5.65)   0.021
  rs3136558    *IL1B*      intron            1.86 (1.14, 3.03)                            0.014                                      0.94 (0.68, 1.30)   0.71     0.51 (0.28, 0.92)   0.025
  rs17313265   *NOD2*      intron            0.70 (0.28, 1.75)                            0.45                                       1.98 (1.23, 3.19)   0.0052   2.82 (1.05, 7.53)   0.039
  rs6349       *SLC6A3*    coding A577A      0.36 (0.14, 0.97)                            0.044                                      1.19 (0.83, 1.71)   0.35     3.28 (1.14, 9.40)   0.027
  rs11904548   *STAT1*     intron            1.89 (1.05, 3.43)                            0.035                                      0.90 (0.63, 1.29)   0.56     0.47 (0.24, 0.96)   0.037
  rs13029247   *STAT1*     intron            0.59 (0.32, 1.08)                            0.087                                      1.29 (0.95, 1.76)   0.11     2.19 (1.13, 4.24)   0.021
  rs16833157   *STAT1*     intron            1.74 (0.94, 3.21)                            0.078                                      0.75 (0.52, 1.09)   0.13     0.43 (0.21, 0.90)   0.024
  rs1914408    *STAT1*     intron            0.40 (0.18, 0.87)                            0.021                                      1.19 (0.90, 1.58)   0.22     2.98 (1.34, 6.62)   0.0074
  rs2066804    *STAT1*     intron            0.47 (0.23, 0.94)                            0.032                                      1.28 (0.97, 1.70)   0.08     2.74 (1.33, 5.63)   0.006
  rs2280235    *STAT1*     intron            0.39 (0.18, 0.84)                            0.017                                      1.22 (0.92, 1.61)   0.17     3.14 (1.42, 6.91)   0.0046
  rs3771300    *STAT1*     intron            1.62 (1.05, 2.49)                            0.028                                      0.84 (0.64, 1.10)   0.20     0.52 (0.32, 0.85)   0.009
  rs7576984    *STAT1*     intron            1.70 (0.98, 2.98)                            0.061                                      0.74 (0.52, 1.04)   0.086    0.43 (0.22, 0.84)   0.014
  rs11466716   *TICAM1*    flanking 5' UTR   0.42 (0.20, 0.88)                            0.022                                      0.99 (0.72, 1.37)   0.95     2.37 (1.06, 5.29)   0.035
  rs7864330    *TLR4*      intron            2.14 (1.17, 3.92)                            0.014                                      0.89 (0.61, 1.31)   0.56     0.42 (0.21, 0.84)   0.015
  rs5743809    *TLR6*      coding L194P      3.47 (1.57, 7.66)                            0.0020                                     1.12 (0.80, 1.58)   0.50     0.32 (0.14, 0.75)   0.0086
  rs5743812    *TLR6*      coding T287T      3.59 (1.62, 7.92)                            0.0016                                     1.15 (0.81, 1.64)   0.44     0.32 (0.14, 0.75)   0.0085
  rs5743832    *TLR6*      flanking 3' UTR   4.23 (1.84, 9.76)                            0.00071                                    1.10 (0.78, 1.56)   0.59     0.26 (0.11, 0.63)   0.0027

Odds ratios for children and adults were derived from the models containing the age x genotype interaction term, and are not interpretable independently from the interaction term.

###### 

Results of genetic association analysis of RSTR phenotype (SNPs with nominal p-values \<0.05

  SNP          Gene        Location          OR (95% CI)        p       Best Model
  ------------ ----------- ----------------- ------------------ ------- ------------
  rs3024490    *IL10*      intron            0.59(0.37, 0.96)   0.032   Dom
  rs2243115    *IL12A*     intron            1.72(1.01, 2.92)   0.044   Add
  rs17852635   *IL12RB1*   coding P228P      0.30(0.11, 0.82)   0.019   Dom
  rs2066445    *IL12RB2*   intron            0.62(0.39, 0.99)   0.046   Dom
  rs2709800    *NOD1*      intron            0.53(0.3, 0.96)    0.036   Dom
  rs932272     *NOD1*      intron            0.57(0.34, 0.95)   0.031   Dom
  rs6500328    *NOD2*      intron            2.44(1.01. 5.88)   0.047   Dom
  rs2111234    *NOD2*      intron            1.56(1.07, 2.28)   0.020   Add
  rs409588     *SLC6A3*    intron            0.68(0.5, 0.93)    0.014   Add
  rs456082     *SLC6A3*    intron            0.70(0.51, 0.96)   0.025   Add
  rs464061     *SLC6A3*    intron            0.70(0.51, 0.96)   0.025   Add
  rs7575823    *STAT1*     intron            0.59(0.35, 0.98)   0.043   Dom
  rs2052834    *TICAM2*    flanking 5' UTR   0.66(0.46, 0.97)   0.032   Add
  rs4235232    *TLR2*      intron            1.83(1.03, 3.24)   0.040   Dom
  rs5030710    *TLR4*      coding S105S      0.46(0.24, 0.88)   0.020   Dom
  rs5030729    *TLR4*      intron            0.48(0.25, 0.91)   0.026   Dom
  rs5743942    *TOLLIP*    intron            2.20(1.19, 4.06)   0.012   Dom

###### 

Genotype x age interaction analysis of RSTR

                                        Children^[\*](#TFN5){ref-type="table-fn"}^   Adults^[\*](#TFN5){ref-type="table-fn"}^   Interaction                                       
  ------------ --------- -------------- -------------------------------------------- ------------------------------------------ ------------------- -------- -------------------- --------
  rs1059293    IFNGR2    3UTR           0.76 (0.44, 1.33)                            0.34                                       1.92 (0.93, 3.96)   0.079    2.51 (1.04, 6.08)    0.041
  rs2284555    IFNGR2    intron         0.76 (0.43, 1.34)                            0.34                                       1.95 (0.95, 4.00)   0.070    2.56 (1.06, 6.18)    0.037
  rs365179     IL12RB1   intron         0.66 (0.40, 1.09)                            0.10                                       1.70 (0.91, 3.18)   0.098    2.59 (1.21, 5.52)    0.014
  rs375947     IL12RB1   coding M365T   0.55 (0.33, 0.92)                            0.023                                      1.59 (0.86, 2.96)   0.14     2.89 (1.36, 6.15)    0.006
  rs376008     IL12RB1   intron         0.69 (0.43, 1.10)                            0.12                                       1.85 (0.94, 3.64)   0.077    2.69 (1.19, 6.06)    0.017
  rs382634     IL12RB1   intron         0.68 (0.42, 1.10)                            0.12                                       1.89 (0.97, 3.71)   0.063    2.79 (1.24, 6.28)    0.013
  rs429774     IL12RB1   intron         0.70 (0.44, 1.12)                            0.14                                       2.00 (1.05, 3.80)   0.034    2.85 (1.31, 6.18)    0.0082
  rs845375     IL12RB1   intron         0.72 (0.40, 1.28)                            0.26                                       1.76 (0.84, 3.66)   0.13     2.44 (1.05, 5.66)    0.038
  rs11209052   IL12RB2   intron         2.22 (1.27, 3.88)                            0.005                                      0.30 (0.05, 1.77)   0.18     0.14 (0.02, 0.85)    0.033
  rs12091150   IL12RB2   intron         1.49 (0.95, 2.34)                            0.085                                      0.46 (0.21, 1.01)   0.053    0.31 (0.13, 0.76)    0.011
  rs2307147    IL12RB2   coding D26D    1.52 (0.97, 2.39)                            0.069                                      0.46 (0.21, 1.02)   0.055    0.30 (0.12, 0.74)    0.0094
  rs3882891    IL18      intron         0.89 (0.60, 1.31)                            0.55                                       1.86 (0.98, 3.52)   0.057    2.10 (1.04, 4.26)    0.040
  rs3783587    IL1A      intron         0.74 (0.21, 2.58)                            0.64                                       3.22 (1.17, 8.84)   0.023    4.33 (1.14, 16.52)   0.032
  rs28363167   SLC6A3    3UTR           0.35 (0.06, 1.97)                            0.23                                       3.05 (1.01, 9.18)   0.047    8.82 (1.33, 58.63)   0.024
  rs464049     SLC6A3    intron         1.46 (0.96, 2.23)                            0.08                                       0.55 (0.22, 1.35)   0.19     0.38 (0.14, 1.00)    0.049
  rs2280235    STAT1     intron         0.88 (0.58, 1.34)                            0.55                                       1.80 (0.94, 3.47)   0.078    2.05 (1.01, 4.18)    0.048
  rs10983756   TLR4      intron         0.59 (0.23, 1.52)                            0.28                                       3.39 (1.43, 8.02)   0.0054   5.72 (1.59, 20.55)   0.0076
  rs12344353   TLR4      intron         0.57 (0.30, 1.10)                            0.096                                      1.67 (0.74, 3.78)   0.22     2.93 (1.06, 8.05)    0.037
  rs5030717    TLR4      intron         1.31 (0.81, 2.13)                            0.27                                       0.48 (0.19, 1.19)   0.11     0.37 (0.14, 0.99)    0.049
  rs5743808    TLR6      coding I120T   0.77 (0.41, 1.42)                            0.40                                       2.00 (1.13, 3.56)   0.018    2.61 (1.18, 5.79)    0.018

Odds ratios for children and adults were derived from the models containing the age x genotype interaction term, and are not interpretable independently from the interaction term.
